Lorazepam vs Stiripentol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Lorazepam

Marketed by Hikma Pharmaceuticals PLC

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Stiripentol

Marketed by Biocodex

Approved in Epilepsysmall molecule
Weak signal

NCT07176832 · Phase 1 · completed

This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLorazepamStiripentol
Seizure frequency, % change—Not posted · NCT00004297—Not reported
50% responder rate—Not posted · NCT00004297—Not reported
Seizure freedom—Not posted · NCT00004297—Not reported

Seizure frequency, % change

Lorazepam
—Not posted · NCT00004297
Stiripentol
—Not reported

50% responder rate

Lorazepam
—Not posted · NCT00004297
Stiripentol
—Not reported

Seizure freedom

Lorazepam
—Not posted · NCT00004297
Stiripentol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lorazepam: registry results are on file for Epilepsy, but their comparison mappings are not yet available.

Stiripentol: no structured comparison results are available for Epilepsy.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lorazepam's landscape · Stiripentol's landscape